Revolution Medicines reported interim and final results from its registrational Phase 3 RASolute 302 trial of daraxonrasib in metastatic pancreatic ductal adenocarcinoma, showing median overall survival of 13.2 months versus 6.7 months with standard chemotherapy. The company said the results met primary endpoints at an interim checkpoint and that the study was ended early. Revolution plans to seek U.S. regulatory review under the FDA’s national priority voucher pilot program previously granted for daraxonrasib, aiming for a fast track after data submission. Separately, analysts and company messaging highlighted that the benefit aligns with earlier signals from RAS-mutant patient populations, though Revolution did not release full primary endpoint stratification details in the materials summarized here. Wall Street reaction reflected the magnitude of the survival delta, with the company positioning daraxonrasib as a targeted approach in a disease area with historically limited options. The readout also renews focus on RAS-family biology as drug developers pursue mutation-directed strategies in pancreatic cancer. Overall, Revolution’s data provide one of the clearest late-stage signals in years for a RAS inhibitor in this setting, with the next milestone centered on FDA submission timing and the scope of regulator-required evidence.